Skip to main content
SpringerLink
Log in

Interactions between corticosteroids and β2-agonists

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

In vitro studies have demonstrated numerous ways in which β2-agonists and corticosteroids may interact. Together with evidence of improved control of airway diseases using a combination therapy of inhaled corticosteroids and long-acting β-agonists compared with treatment with either drug alone, this suggests that there may be a beneficial synergy between these two classes of medication. However, a positive interaction has not been clearly demonstrated in vivo. There is little evidence that β2-agonists enhance the anti-inflammatory actions of inhaled corticosteroids. Corticosteroids do not enhance the bronchodilator response to β2-agonists, nor do they appear to prevent the development of tolerance during chronic β2-agonist treatment. The evidence that high doses of corticosteroids can reverse tolerance to β2-agonists is conflicting. Most of the clinical benefits from combinations using inhaled corticosteroids and long-acting β-agonists to treat asthma could result from additive or complimentary effects of the drugs on different parts of the disease process. Nevertheless, there are several studies in which the combination of a long- or short-acting β-agonist with an inhaled corticosteroid appears to have provided more than additive clinical benefits. The issue warrants further study. Combined inhaled corticosteroid/ β-agonist treatment will remain the basis of asthma management for the forseeable future, and although the overall clinical benefit of the combination is no longer in doubt, there is more to learn about maximizing this benefit and minimizing adverse effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lazarus, S. C., Boushey H. A., Fahy J. V., et al. (2001), Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 285, 2583–2593.

    Article  PubMed  CAS  Google Scholar 

  2. Lemanske, R. F. Jr., Sorkness C. A., Mauger E. A., et al. (2001), Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 285, 2594–2603.

    Article  PubMed  CAS  Google Scholar 

  3. Nelson, Harold S., Weiss Scott T., Bleecker Eugene R., et al. (2006), The Salmeterol Multicenter Asthma Research Trial: A Comparison of Usual Pharmaco-therapy for Asthma or Usual Pharmacotherapy Plus Salmeterol. Chest 129, 15–26.

    Article  PubMed  CAS  Google Scholar 

  4. Pauwels, R. A., Lofdahl C. G., Postma D. S., et al. (1997), Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 337, 1405–1411.

    Article  PubMed  CAS  Google Scholar 

  5. Ni, C. M., Greenstone I., Danish A., et al. (2005), Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst. Rev. CD005535.

  6. Bateman, E. D., Boushey H. A., Bousquet J., et al. (2004), Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 170, 836–844.

    Article  PubMed  Google Scholar 

  7. Hancox, R. J. and Taylor D. R. (2001), Long-acting beta-agonist treatment in patients with persistent asthma already receiving inhaled corticosteroids. BioDrugs 15, 11–24.

    Article  PubMed  CAS  Google Scholar 

  8. British Thoracic Society, Scottish Intercollegiate Guidelines Network. (2003), British guideline on the management of asthma. Thorax 58, 1–83.

    Article  Google Scholar 

  9. Workshop Report, Global Strategy for Asthma Management and Prevention. (2005), http://www. ginasthma.org/Accessed January 21, 2006.

  10. Calverley, P., Pauwels R., Vestbo J., et al. (2003), Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361, 449–456.

    Article  PubMed  CAS  Google Scholar 

  11. Szafranski, W., Cukier A., Ramirez A., et al. (2003), Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 21, 74–81.

    Article  PubMed  CAS  Google Scholar 

  12. Nannini, L., Cates, C. J., Lasserson T. J., and Poole, P. (2004), Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. CD003794.

  13. Peachell, P. (2005), Targeting the mast cell in asthma. Curr. Opin. Pharmacol. 5, 251–256.

    Article  PubMed  CAS  Google Scholar 

  14. Barnes, P. J. (2002), Scientific rationale for inhaled combination therapy with long-acting beta-agonists and corticosteroids. Eur. Respir. J. 19, 182–191.

    Article  PubMed  CAS  Google Scholar 

  15. Remington, T. L. and Digiovine B. (2005), Long-acting beta-agonists: anti-inflammatory properties and synergy with corticosteroids in asthma. Curr. Opin. Pulm. Med. 11, 74–78.

    Article  PubMed  Google Scholar 

  16. Currie, G. P., Stenback S., and Lipworth B. J. (2003), Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma. Br. J. Clin. Pharmacol. 56, 11–17.

    Article  PubMed  CAS  Google Scholar 

  17. Johnson, M. (2004), Interactions between corticosteroids and beta2-agonists in asthma and chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 1, 200–206.

    Article  PubMed  CAS  Google Scholar 

  18. Currie, G. P., Lee D. K., and Wilson A. M. (2005), Effects of dual therapy with corticosteroids plus long acting beta2-agonists in asthma. Respir. Med. 99, 683–694.

    Article  PubMed  Google Scholar 

  19. Taylor, D. R. and Hancox R. J. (2000), Interactions between corticosteroids and beta agonists. Thorax 55, 595–602.

    Article  PubMed  CAS  Google Scholar 

  20. Hadcock, J. R. and Malbon C. C. (1988), Regulation of beta-adrenergic receptors by “permissive” hormones: glucocorticoids increase steady-state levels of receptor mRNA. Proc. Natl. Acad. Sci. USA 85, 8415–8419.

    Article  PubMed  CAS  Google Scholar 

  21. Baraniuk, J. N., Ali M., Brody D., et al. (1997), Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. Am. J. Respir. Crit. Care Med. 155, 704–710.

    PubMed  CAS  Google Scholar 

  22. Malbon, C. C. and Hadcock J. R. (1988), Evidence that glucocorticoid response elements in the 5′-noncoding region of the hamster beta2-adrenergic receptor gene are obligate for glucocorticoid regulation of receptor mRNA levels. Biochem. Biophys. Res. Commun. 154, 676–681.

    Article  PubMed  CAS  Google Scholar 

  23. Mak, J. C., Nishikawa M., and Barnes P. J. (1995), Glucocorticosteroids increase beta2-adrenergic receptor transcription in human lung. Am. J. Physiol. 268, L41-L46.

    PubMed  CAS  Google Scholar 

  24. Hui, K. K., Conolly M. E., and Tashkin D. P. (1982), Reversal of human lymphocyte beta-adrenoceptor desensitization by glucocorticoids. Clin. Pharmacol. Ther. 32, 566–571.

    Article  PubMed  CAS  Google Scholar 

  25. Peters, M. J., Adcock I. M., Brown C. R., and Barnes P. J. (1993), Beta-agonist inhibition of steroid-receptor DNA-binding activity in human lung. Am. Rev. Respir. Dis. 147, A772.

    Google Scholar 

  26. Adcock, I. M., Brown C. R., Gelder C. M., Shirasaki H., Peters M. J., and Barnes P. J. (1995), Effects of glucocorticoids on transcription factor activation in human peripheral blood mononuclear cells. Am. J. Physiol. 268, C331-C338.

    PubMed  CAS  Google Scholar 

  27. Peters, M. J., Adcock I. M., Brown C. R., and Barnes P. J. (1995), Beta-adrenoceptor agonists interfere with glucocorticoid receptor DNA binding in rat lung. Eur. J. Pharmacol. 289, 275–281.

    Article  PubMed  CAS  Google Scholar 

  28. Korn, S. H., Wouters, E. F., Wesseling G., Arends J. W., and Thunnissen F. B. (1998), Interaction between glucocorticoids and beta2-agonists: alpha and beta glucocorticoid-receptor mRNA expression in human bronchial epithelial cells. Biochem. Pharmacol. 56, 1561–1569.

    Article  PubMed  CAS  Google Scholar 

  29. Nielson, C. P. and Hadjokas N. E. (1998), Beta-adrenoceptor agonists block corticosteroid inhibition in eosinophils. Am. J. Respir. Crit. Care Med. 157, 184–191.

    PubMed  CAS  Google Scholar 

  30. Tse, R., Marroquin B. A., Dorscheid D. R., and White S. R. (2003), Beta-adrenergic agoists inhibit corticosteroid-induced apoptosis of airway epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 285, L393-L404.

    PubMed  CAS  Google Scholar 

  31. Vanacker, N. J., Palmans E., Pauwels R. A., and Kips J. C. (2002), Effect of combining salmeterol and fluticasone on the progression of airway remodeling. Am. J. Respir. Crit. Care Med. 166, 1128–1134.

    Article  PubMed  Google Scholar 

  32. Oddera, S., Silvestri M., Testi R., and Rossi G. A. (1998), Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation. Respiration. 65, 199–204.

    Article  PubMed  CAS  Google Scholar 

  33. Profita, M., Gagliardo R., Di Giorgi R., et al. (2005), Biochemical interaction between effects of beclomethasone dipropionate and sulbutamol or formoterol in sputum cells from mild to moderate asthmatics. Allergy. 60, 323–329.

    Article  PubMed  CAS  Google Scholar 

  34. Pang, L. and Knox A. J. (2000), Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells. Am. J. Respir. Cell Mol. Biol. 23, 79–85.

    PubMed  CAS  Google Scholar 

  35. Pang, L. and Knox A. J. (2001), Regulation of TNF-alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta2-agonists and corticosteroids. FASEB J. 15, 261–269.

    Article  PubMed  CAS  Google Scholar 

  36. Korn, S. H., Jerre A., and Brattsand R. (2001), Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells. Eur. Respir. J. 17, 1070–1077.

    Article  PubMed  CAS  Google Scholar 

  37. Nie, M., Knox A. J., and Pang L. (2005), beta2-Adrenoceptor agonists, like glucocorticoids, repress eotaxin gene transcription by selective inhibition of histone H4 acetylation. J. Immunol. 175, 478–486.

    PubMed  CAS  Google Scholar 

  38. Oddera, S., Silvestri M., Lantero S., Sacco O., and Rossi G. A. (1998), Downregulation of the expression of intercellular adhesion molecule (ICAM)-1 on bronchial epithelial cells by fenoterol, a beta2-adrenoceptor agonists. J. Asthma. 35, 401–408.

    PubMed  CAS  Google Scholar 

  39. Silvestri, M., Fregonese L., Sabatini F., Dasic G., and Rossi G. A. (2001), Fluticasone and salmeterol downregulate in vitro, fibroblast proliferation and ICAM-1 or H-CAM expression. Eur. Respir. J. 18, 139–145.

    Article  PubMed  CAS  Google Scholar 

  40. Pace, E., Gagliardo R., Melis M., et al. (2004), Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma. J. Allergy Clin. Immunol. 114, 1216–1223.

    Article  PubMed  CAS  Google Scholar 

  41. Dong, Y., Aronsson, M., Gustafsson J. A., and Okret S. (1989), The mechanism of cAMP-induced glucocorticoid receptor expression. Correlation to cellular glucocorticoid response. J. Biol. Chem. 264, 13,679–13,683.

    CAS  Google Scholar 

  42. Eickelberg, O., Roth M., Lorx R., et al. (1999), Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J. Biol. Chem. 274, 1005–1010.

    Article  PubMed  CAS  Google Scholar 

  43. Roth, M., Johnson P. R., Rudiger J. J., et al. (2002), Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 360, 1293–1299.

    Article  PubMed  CAS  Google Scholar 

  44. Losel, R. M., Falkenstein E., Feuring M., et al. (2003), Nongenomic steroid action: controversies, questions, and answers. Physiol. Rev. 83, 965–1016.

    PubMed  Google Scholar 

  45. Johnson, M. (2006), Molecular mechanisms of beta2-adrenergic receptor function, response, and regulation. J. Allergy Clin. Immunol. 117, 18–24.

    Article  PubMed  CAS  Google Scholar 

  46. Torphy, T. J. (1994), Beta-adrenoceptors, cAMP and airway smooth muscle relaxation: challenges to the dogma. Trends Pharmacol. Sci. 15, 370–374.

    Article  PubMed  CAS  Google Scholar 

  47. Usmani, O. S., Ito K., Maneechotesuwan K., et al. (2005), Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am. J. Respir. Crit. Care Med. 172, 704–712.

    Article  PubMed  Google Scholar 

  48. Lee, D. K., Jackson C. M., Currie G. P., Cockburn W. J., and Lipworth B. J. (2003), Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. Br. J. Clin. Pharmacol. 56, 494–500.

    Article  PubMed  CAS  Google Scholar 

  49. Aziz, I., Wilson A. M., and Lipworth B. J. (2000), Effects of once-daily formoterol and budesonide given alone or in combination on surrogate inflammatory markers in asthmatic adults. Chest 118, 1049–1058.

    Article  PubMed  CAS  Google Scholar 

  50. Gardiner, P. V., Ward C., Booth H., Allison A., Hendrick D. J., and Walters E. H. (1994), Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am. J. Respir. Crit. Care Med. 150, 1006–1011.

    PubMed  CAS  Google Scholar 

  51. Overbeek, S. E., Mulder P. G., Baelemans S. M., Hoogsteden H. C., and Prins J. B. (2005), Formoterol added to low-dose budesonide has no additional antiinflammatory effect in asthmatic patients. Chest 128, 1121–1127.

    Article  PubMed  CAS  Google Scholar 

  52. Greening, A. P., Ind P. W., Northfield M., and Shaw G. (1994), Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 344, 219–224.

    Article  PubMed  CAS  Google Scholar 

  53. Woolcock, A., Lundback B., Ringdal N., and Jacques L. A. (1996), Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir. Crit. Care Med. 153, 1481–1488.

    PubMed  CAS  Google Scholar 

  54. Kips, J. C., O'Connor B. J., Inman M. D., et al. (2000), A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am. J. Respir. Crit. Care Med. 161, 996–1001.

    PubMed  CAS  Google Scholar 

  55. Currie, G. P., Bates C. E., Lee D. K., Jackson C. M., and Lipworth B. J. (2003), Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. Eur. J. Clin. Pharmacol. 59, 11–15.

    PubMed  CAS  Google Scholar 

  56. Hancox, R. J., Cowan J. O., Flannery E. M., et al. (1999), Randomised trial of an inhaled beta2 agonist, inhaled corticosteroid and their combination in the treatment of asthma. Thorax 54, 482–487.

    PubMed  CAS  Google Scholar 

  57. Aldridge, R. E., Hancox R. J., Taylor D. R., et al. (2000), Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am. J. Respir. Crit. Care Med. 161, 1459–1464.

    PubMed  CAS  Google Scholar 

  58. Hancox, R. J., Stevens D. A., Adcock I. M., Barnes P. J., and Taylor D. R. (1999), Effects of inhaled beta agonist and corticosteroid treatment on nuclear transcription factors in bronchial mucosa in asthma. Thorax 54, 488–492.

    PubMed  CAS  Google Scholar 

  59. Li, X., Ward C., Thien F., et al. (1999), An antiin-flammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am. J. Respir. Crit. Care Med. 160, 1493–1499.

    PubMed  CAS  Google Scholar 

  60. Wallin, A., Sue-Chu M., Bjermer L., et al. (2003), Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. J. Allergy Clin. Immunol. 112, 72–78.

    Article  PubMed  CAS  Google Scholar 

  61. Wallin, A., Sandstrom T., Soderberg M., et al. (1999), The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflamma tion and clinical indices in mild asthma. Am. J. Respir. Crit. Care Med. 159, 79–86.

    PubMed  CAS  Google Scholar 

  62. Davies, A. O., De Lean A., and Lefkowitz R. J. (1981), Myocardial beta-adrenergic receptors from adrenalectomized rats: impaired formation of high-affinity agonist-receptor complexes. Endocrinology 108, 720–722.

    Article  PubMed  CAS  Google Scholar 

  63. Davies, A. O. and Lefkowitz R. J. (1984), Regulation of beta-adrenergic receptors by steroid hormones. Annu. Rev. Physiol. 46, 119–130.

    Article  PubMed  CAS  Google Scholar 

  64. Shenfield, G. M., Hodson, M. E., Clarke, S. W., and Paterson J. W. (1975), Interaction of corticosteroids and catecholamines in the treatment of asthma. Thorax 30, 430–435.

    PubMed  CAS  Google Scholar 

  65. Molema, J., Lammers, J. W., van Herwaarden C. L., and Folgering, H. T. (1988), Effects of inhaled beclomethasone dipropionate on beta2-receptor function in the airways and adrenal responsiveness in bronchial asthma. Eur. J. Clin. Pharmacol. 34, 577–583.

    Article  PubMed  CAS  Google Scholar 

  66. Wempe, J. B., Postma, D. S., Breederveld, N., et al. (1992), Separate and combined effects of corticosteroids and bronchodilators on airflow obstruction and airway hyperresponsiveness in asthma. J. Allergy Clin. Immunol. 89, 679–687.

    Article  PubMed  CAS  Google Scholar 

  67. Curzon, P. G., Martin M. A., Cooke N. J., and Muers M. F. (1983), Effect of oral prednisolone on response to salbutamol and ipratropium bromide aerosols in patients with chronic airflow obstruction. Thorax 38, 601–604.

    PubMed  CAS  Google Scholar 

  68. Grandordy, B., Belmatoug N, Morelle A, De Lauture D, and Marsac J. (1987), Effect of betamethasone on airway obstruction and bronchial response to salbutamol in prednisolone resistant asthma. Thorax 42, 65–71.

    PubMed  CAS  Google Scholar 

  69. Stephan, W. C., Chick T. W., Avner B. P., and Jenne J. W. (1980), Tachyphylaxis to inhaled isoproterenol and the effect of methylprednisolone in dogs. J. Allergy Clin. Immunol. 65, 105–109.

    Article  PubMed  CAS  Google Scholar 

  70. Geddes, B. A., Jones T. R., Dvorsky R. J., and Lefcoe N. M. (1974), Interaction of glucocorticoids and bronchodilators on isolated guinea pig tracheal and human bronchial smooth muscle. Am. Rev. Respir. Dis. 110, 420–427.

    PubMed  CAS  Google Scholar 

  71. Brodde, O. E., Brinkmann M., Schemuth R., O'Hara N., and Daul A. (1985), Terbutaline-induced desensitization of human lymphocyte β2-adrenoceptors. Accelerated restoration of β-adrenoceptor responsiveness by prednisone and ketotifen. J. Clin. Invest. 76, 1096–1101.

    Article  PubMed  CAS  Google Scholar 

  72. Brodde, O. E., Howe U., Egerszegi S., Konietzko N., and Michel M. C. (1988), Effect of prednisolone and ketotifen on beta2-adrenoceptors in asthmatic patients receiving beta2-bronchodilators. Eur. J. Clin. Pharmacol. 34, 145–150.

    Article  PubMed  CAS  Google Scholar 

  73. Ellul-Micallef, R. and Fenech F. F. (1975), Effect of intravenous prednisolone in asthmatics with diminished adrenergic responsiveness. Lancet 2, 1269–1271.

    Article  PubMed  CAS  Google Scholar 

  74. Pansegrouw, D. F., Weich D. J., and le Roux F. P. (1991), Beta-adrenergic receptor tachyphylaxis in acute severe asthma. A preliminary communication. S. Afr. Med. J. 80, 229,230.

    PubMed  CAS  Google Scholar 

  75. Holgate, S. T., C. J. Baldwin, and A. E. Tattersfield. (1977), beta-adrenergic agonist resistance in normal human airways. Lancet 2, 375–377.

    Article  PubMed  CAS  Google Scholar 

  76. Cazzola, M., Santus, P., Di Marco F., et al. (2004), Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD. Pulm. Pharmacol. Ther. 17, 121–125.

    Article  PubMed  CAS  Google Scholar 

  77. Tan K. S., Grove A., McLean A., Gnosspelius Y., Hall I. P., Lipworth B. J. (1997), Systemtic, corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am. J. Respir. Crit. Care Med. 156, 28–35.

    PubMed  CAS  Google Scholar 

  78. Lipworth, B. J. and Aziz I. (2000), Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. Chest 117, 156–162.

    Article  PubMed  CAS  Google Scholar 

  79. Jones, S. L., Cowan J. O., Flannery E. M., Hancox R. J., Herbison G. P., and Taylor D. R. (2001), Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. Eur. Respir. J. 17, 368–373.

    Article  PubMed  CAS  Google Scholar 

  80. Hancox, R. J., Aldridge R. E., Cowan J. O., et al. (1999), Tolerance to beta-agonists during acute bronchoconstriction. Eur. Respir. 14, 283–287.

    Article  CAS  Google Scholar 

  81. Yates, D. H., Kharitonov S. A., and Barnes P. J. (1996), An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist. Am. J. Respir. Crit. Care Med. 154, 1603–1607.

    PubMed  CAS  Google Scholar 

  82. Booth, H., Bish R., Walters J., Whitehead F., and Walters E. H. (1996), Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax 51, 1100–1104.

    Article  PubMed  CAS  Google Scholar 

  83. Kalra, S., Swystun V. A., Bhagat R., and Cockcroft D. W. (1996), Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 109, 953–956.

    PubMed  CAS  Google Scholar 

  84. Simons, F. E., Gerstner T. V., and Cheang M. S. (1997), Tolerance to the, bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 99, 655–659.

    Article  PubMed  CAS  Google Scholar 

  85. Boulet, L. P., Cartier A., Milot J., Cote J., Malo J. L., and Laviolette M. (1998), Tolerance to the protective effects of salmeterol on methacholine-induced bronchconstriction: influence of inhaled corticosteroids. Eur. Repir. J. 11, 1091–1097.

    Article  CAS  Google Scholar 

  86. Aziz, J., Tan K. S., Hall I. P., Devlin M. M., and Lipworth B. J. (1998), Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol. Eur. Respir. J. 12, 580–584.

    Article  PubMed  CAS  Google Scholar 

  87. Grootendorst, D. C., Sterk P. J., and Heijerman H. G. (2001), Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma. Eur. Respir. J. 17, 374–379.

    Article  PubMed  CAS  Google Scholar 

  88. Yates, D. H., Worsdell M., and Barnes P. J. (1998), Effect of an inhaled glucocorticosteroid on mast cell and smooth muscle beta2 adrenergic tolerance in mild asthma. Thorax 53, 110–113.

    PubMed  CAS  Google Scholar 

  89. Giannini, D., Bacci E., Dente F. L., et al. (1999), Inhaled beclomethasone dipropionate reverts tolerance to the protective effect of salmeterol on allergen challenge. Chest 115, 629–634.

    Article  PubMed  CAS  Google Scholar 

  90. Paggiaro, P. L., Giannini, D., Di Franco A., et al. (2005), Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge. Pulm. Pharmacol. Ther. [Epub ahead of print].

  91. Gibson, P., Powell H., Ducharme F., and Gibson, P. (2005), Long-acting beta2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults and children. Cochrane Database Syst. Rev. CD005076.

  92. Wong, C. S., Wahedna I., Pavord I. D., and Tattersfield A. E. (1994), Effect of regular terbutaline and budesonide on bronchial reactivity to allergen challenge. Am. J. Respir. Crit. Care Med. 150, 1268–1273.

    PubMed  CAS  Google Scholar 

  93. Cockcroft, D. W., Swystun V. A., and Bhagat R. (1995), Interaction of inhaled beta2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Am. J. Respir. Crit. Care Med. 152, 1485–1489.

    PubMed  CAS  Google Scholar 

  94. Aziz, I., McFarlane L. C., and Lipworth B. J. (1998), Concomitant inhaled corticosteroid resensitises cardiac beta2-adrenoceptors in the presence of long-acting, beta2-agonist therapy. Eur. J. Clin. Pharmacol. 54, 377–381.

    Article  PubMed  CAS  Google Scholar 

  95. Tan, K. S., McFarlane L. C., and Lipworth B. J. (1998), Concomitant administration of low-dose prednisolone protects against in vivo beta2-adrenoceptor subsensitivity induced by regular formoterol. Chest 113, 34–41.

    PubMed  CAS  Google Scholar 

  96. Taylor, D. R., Wilkins G. T., Herbison G. P., and Flannery E. M. (1992), Interaction between corticosteroid and beta-agonist drugs. Biochemical and cardiovascular effects in normal subjects. Chest 102, 519–524.

    Article  PubMed  CAS  Google Scholar 

  97. Salpeter, S. R., Ormiston T. M., and Salpeter E. E. (2004), Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 125, 2309–2321.

    Article  PubMed  CAS  Google Scholar 

  98. Nelson, H. S., Chapman K. R., Pyke S. D., Johnson M., and Pritchard J. N. (2003), Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J. Allergy Clin. Immunol. 112, 29–36.

    Article  PubMed  CAS  Google Scholar 

  99. Zetterstrom, O., Buhl R., Mellem H., et al. (2001), Improved asthma control with budesonide/ formoterol in a single inhaler, compared with budesonide alone. Eur. Respir. J. 18, 262–268.

    Article  PubMed  CAS  Google Scholar 

  100. Rosenhall, L., Elvstrand A., Tilling B., et al. (2003), One-year safety and efficacy of budesonide/ formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. Respir. Med. 97, 702–708.

    Article  PubMed  CAS  Google Scholar 

  101. Wilding, P. J., Clark M. M., Oborne J., Bennett J. A., and Tattersfield A. E. (1996), Effect of regular terbutaline on the airway response to inhaled budesonide. Thorax 51, 989–992.

    PubMed  CAS  Google Scholar 

  102. Barnes, P. J. and O'Connor B. J. (1995), Use of a fixed combination beta2-agonist and steroid dry powder inhaler in asthma. Am. J. Respir. Crit. Care Med. 151, 1053–1057.

    PubMed  CAS  Google Scholar 

  103. Taylor, D. R., Town G. I., Herbison G. P., et al. (1998), Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax 53, 744–752.

    Article  PubMed  CAS  Google Scholar 

  104. Sears, M. R., Taylor D. R., Print C. G., et al. (1990). Regular inhalted beta-agonist treatment in bronchial asthma. Lancet 336, 1391–1396.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Preventive and Social Medicine, Dunedin School of Medicine, Dunedin, New Zealand

    Robert J. Hancox

  2. Department of Respiratory Medicine, Waikato Hospital, Hamilton, New Zealand

    Robert J. Hancox

Authors
  1. Robert J. Hancox
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hancox, R.J. Interactions between corticosteroids and β2-agonists. Clinic Rev Allerg Immunol 31, 231–245 (2006). https://doi.org/10.1385/CRIAI:31:2:231

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/CRIAI:31:2:231

β-Agonist

Search

Navigation